Heparin-Induced Thrombocytopenia and Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma After Hepatectomy: A Case Report

Portal vein thrombosis and heparin-induced thrombocytopenia (HIT) caused by postoperative heparin administration is a potentially fatal disease. There have been a few cases of portal vein thrombosis and HIT developing after hepatectomy. We report a rare case of HIT and portal vein thrombosis after hepatectomy. A 79-year-old woman with liver cirrhosis and hypertension was referred to our hospital for the evaluation of the elevated tumor marker and liver tumor diagnosed by ultrasonography. In laboratory findings, alpha-fetoprotein and protein induced by vitamin K absence were elevated. Contrast-enhanced computed tomography (CT) scan findings showed that 28 mm and 17 mm diameter, round-shaped tumors enhanced heterogeneously with infiltration in the left hepatic vein and pulmonary embolization. Hepatocellular carcinoma and pulmonary embolism were diagnosed. She underwent lateral segmentectomy along with venous tumor embolus resection. Pathological findings showed that the tumor was moderate to well-differentiated adenocarcinoma invading the capsule with liver cirrhosis. Tumor embolization was suspected preoperatively to be an organizing thrombus. After surgery, she was treated with heparin for the prevention of deep venous thrombosis. At postoperative day 15, the sudden onset of the decline of platelets, the activity of antithrombin III, and the elevation of D-dimer were found. On physical examination, there were no symptoms. The 4T's score was 7. CT scan showed a portal vein thrombosis. The antibody for HIT was elevated. HIT was diagnosed. We stopped the heparin and started the argatroban administration. The platelet level increased to the normal range, and the D-dimer level decreased. After the reduction of portal vein and pulmonary thrombosis, she was discharged from the hospital on postoperative day 28.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Explore how this research connects to clinical practice

More peer-reviewed studies in Clinical Trials.

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• Wound healing potential of bark paste of Pongamia pinnata along with hirudotherapy: A case report — Balasooriya D, Karunarathna C, Uluwaduge I (2021)
• AIF-1 and RNASET2 Play Complementary Roles in the Innate Immune Response of Medicinal Leech — Baranzini N et al. (2019)
• Study on the effect of medicinal leech therapy (Hirudo medicinalis) on full-thickness excisional wound healing in the animal model — Zakian A et al. (2022)
• [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] — Knobloch K et al. (2007)
• The duration of rest and feeding greatly affects the re-breeding of ectoparasites: Hirudo verbana, Hirudo medicinalis and Hirudo orientalis — Aminov R, Frolov A, Aminova A (2022)
• Recombinant hirudin in clinical practice: focus on lepirudin — Greinacher A, Lubenow N (2001)

Browse all ASH-analysed research →